Genmab A/S (GMAB) Stock Price, News & Analysis

Company Overview

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners. Its most notable marketed therapies include daratumumab (commercialized as Darzalex®) for multiple myeloma, developed with Johnson & Johnson, and isatuximab (Sarclisa®) for relapsed or refractory multiple myeloma, in partnership with Sanofi. In addition to these approved treatments, Genmab is advancing a pipeline of bispecific and multispecific antibody candidates designed to engage the immune system in novel ways, including its DuoBody® and HexaBody® platforms.

Beyond its core product assets, Genmab maintains strategic alliances across North America, Europe and Asia, leveraging the commercial reach of its partners to bring therapies to patients worldwide. The company operates research facilities in Copenhagen and Utrecht, along with offices in Princeton, New Jersey, to support clinical and regulatory activities in the United States. Genmab’s leadership team, led by President and Chief Executive Officer Jan van de Winkel, PhD, comprises seasoned executives and scientific experts committed to driving innovation in immuno-oncology.

With a focus on sustainable growth, Genmab continues to expand its pipeline and explore new antibody formats aimed at improving response rates and durability of remission for cancer patients. The company’s ongoing clinical trials span multiple tumor types and combination regimens, underscoring its mission to translate cutting-edge antibody science into transformative cancer therapies.

Key Stats

• Today's Range: $33.54 to $34.19
• 50-Day Range: $26.02 to $34.41
• 52-Week Range: $23.62 to $35.43
• Volume: 1.00 million shs
• Average Volume: 2.76 million shs
• Market Capitalization: $20.96 billion
• P/E Ratio: 26.46
• Dividend Yield: N/A
• Price Target: $39.50
• Consensus Rating: Moderate Buy

Genmab A/S Stock Analysis - MarketRank™

Genmab A/S scored higher than 63% of companies evaluated by MarketBeat, and ranked 129th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Genmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Genmab A/S has a consensus price target of $39.50, representing about 17.6% upside from its current price of $33.60.

Amount of Analyst Coverage

Genmab A/S has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 38.46%

Earnings Growth

Earnings for Genmab A/S are expected to grow by 38.46% in the coming year, from $1.17 to $1.62 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genmab A/S is 26.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.27.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genmab A/S is 26.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.43.

Price to Earnings Growth Ratio

Genmab A/S has a PEG Ratio of 2.04. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Genmab A/S has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.24% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 2.73, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genmab A/S has recently increased by 2.84%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genmab A/S does not currently pay a dividend.

Dividend Growth

Genmab A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 5 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genmab A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.54% of the stock of Genmab A/S is held by insiders.

Percentage Held by Institutions

7.07% of the stock of Genmab A/S is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/04/2026
• Wells Fargo 21st Annual Healthcare Conference: 9/09/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GMAB
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: N/A
• Employees: 3,029
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Genmab A/S: $39.50
• High Price Target: $43.00
• Low Price Target: $32.00
• Potential Upside/Downside: +17.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.27
• Trailing P/E Ratio: 26.46
• Forward P/E Ratio: 28.72
• P/E Growth: 2.04
• Net Income: $963 million
• Net Margins: 19.08%
• Pretax Margin: 21.93%
• Return on Equity: 14.89%
• Return on Assets: 7.73%

Debt

• Debt-to-Equity Ratio: 0.81
• Current Ratio: 2.46
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $3.72 billion
• Price / Sales: 5.63
• Cash Flow: $1.57 per share
• Price / Cash Flow: 21.38
• Book Value: $9.55 per share
• Price / Book: 3.52

Miscellaneous

• Outstanding Shares: 623,780,000
• Free Float: 614,172,000
• Market Cap: $20.96 billion
• Optionable: Optionable
• Beta: 0.84